59595-92-5

Basic information

• Product Name: chlorure de dichloro-3,5 hydroxy-4 benzoyle
• Synonyms: chlorure de dichloro-3,5 hydroxy-4 benzoyle
• CAS NO: 59595-92-5
• Molecular Weight: 225.459
• Mol File: 59595-92-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: chlorure de dichloro-3,5 hydroxy-4 benzoyle(CAS DataBase Reference)
• NIST Chemistry Reference: chlorure de dichloro-3,5 hydroxy-4 benzoyle(59595-92-5)
• EPA Substance Registry System: chlorure de dichloro-3,5 hydroxy-4 benzoyle(59595-92-5)

Safety Data

• Hazardous Substances Data: 59595-92-5(Hazardous Substances Data)

Upstream product

• 110-71-4 1,2-dimethoxyethane 
• 3336-41-2 3,5-dichloro-4-hydroxybenzoic acid 

Downstream Products

• 77832-47-4 2-methyl-3-(3,5-dichloro-4-hydroxy-benzoyl)-indolizine 
• 77832-46-3 2-ethyl-3-(3,5-dichloro-4-hydroxy-benzoyl)-indolizine 
• 77832-49-6 (3,5-Dichloro-4-hydroxy-phenyl)-(2-isopropyl-indolizin-3-yl)-methanone 
• 77832-48-5 (3,5-Dichloro-4-hydroxy-phenyl)-(2-propyl-indolizin-3-yl)-methanone 
• 77832-50-9 (3,5-Dichloro-4-hydroxy-phenyl)-(2-phenyl-indolizin-3-yl)-methanone 
• 77832-51-0 [2-(4-Bromo-phenyl)-indolizin-3-yl]-(3,5-dichloro-4-hydroxy-phenyl)-methanone 
• 409366-27-4 (3,5-dichloro-4-hydroxyphenyl)acetic acid methyl ester 
• 725239-75-8 [3,5-dichloro-4-(4-methoxy-phenoxy)-phenyl]-acetic acid methyl ester 
• 788824-08-8 [3,5-dichloro-4-(3-formyl-4-methoxy-phenoxy)-phenyl]-acetic acid methyl ester 
• 788824-22-6 [4-(3-bromo-4-methoxy-phenoxy)-3,5-dichloro-phenyl]-acetic acid methyl ester 
• 725239-76-9 [4-(4-benzyloxy-phenoxy)-3,5-dichloro-phenyl]-acetic acid methyl ester 
• 788824-09-9 5-(2,6-dichloro-4-methoxycarbonylmethyl-phenoxy)-2-hydroxy-benzoic acid 
• 788824-21-5 [3,5-dichloro-4-(6-methoxy-biphenyl-3-yloxy)-phenyl]-acetic acid methyl ester 

Relevant articles and documents

Synthesis of a human urate transporter-1 inhibitor, an arginine vasopressin antagonist, and a 17β-hydroxysteroid dehydrogenase type-3 inhibitor, using ring-expansion of cyclic ketoximes with DIBALH

Synthesis of three clinical candidates for medicines, a human urate transporter-1 inhibitor, an arginine vasopressin antagonist, and a 17β-hydroxysteroid dehydrogenase type-3 inhibitor, is described. These compounds were synthesized via construction of their 3,4-dihydro-2H-benzo[b][1, 4]oxazine, dibenzodiazepine, and dibenzazocine skeletons, respectively, using the reductive ring-expansion reaction of the corresponding bicyclic or tricyclic oximes with diisobutylaluminum hydride.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.